Societal impact assessment

Abundance Potential

Protocol sets out a map of remimazolam evidence for older endoscopy patients

Assessment takeaway

Unknown · insufficient evidence

The target is the planned evidence-mapping review, not remimazolam treatment itself. Its supported potential contribution is limited to helping future research; clinical, access, fairness, and environmental benefits remain unestablished.

AI-generated · Not editor reviewedAssessed 2026-11-19Rubric abundance-potential-v1

This describes conditional potential, not a probability or measured outcome. Unknown values are not zero, and harms are not subtracted from the total.

Assessment scope

Development
A published protocol for a scoping review that will map clinical evidence on remimazolam sedation during gastrointestinal endoscopy in adults aged 65 and older.
Baseline
Before the planned review is completed and used, evidence specific to older endoscopy patients has not been systematically mapped; the protocol says findings from general adult comparisons may not apply to older adults, and existing studies vary in definitions and methods.
Population
Adults aged 65 and older undergoing gastrointestinal endoscopy; any later clinical benefit would depend on researchers and clinicians using the evidence map.
Geography
The planned search covers international and Chinese sources but is limited to English- and Chinese-language reports; applicability across other languages and health systems is not established.
Target assumptions
The review is completed as planned, its evidence map helps shape future trials or guidance, and any later clinical benefit depends on those steps producing and implementing reliable evidence.

Five dimensions

Human wellbeing
Unknown · The protocol reports no review findings or treatment conclusions, so it does not establish a patient wellbeing benefit. Sources: evidence-2658
Affordability and access
Unknown · The supplied evidence does not address treatment costs, affordability, or access to sedation.
Reach and fairness
Unknown · The review's language limits may leave out relevant reports, and there is no evidence of resulting clinical reach or fair access. Sources: evidence-2660
Environment and resources
Unknown · The supplied evidence does not assess environmental effects or resource use.
Scientific capability
1/4 · If completed, the evidence map could identify gaps and help inform future trial design, a limited potential contribution to research capability. The protocol does not report findings or estimate treatment effects. Sources: evidence-2657, evidence-2658, evidence-2661

Evidence, confidence and timing

Evidence maturity

Finding: Early speculative. The available development is a protocol; it reports no generated data and the scoping review findings remain pending.

Societal benefit: Early speculative. Use of the evidence map to inform trials or guidelines is an intended future benefit, not a demonstrated outcome.

Confidence: Low. The source describes planned work and intended uses, not completed review findings or demonstrated effects on care.

Conditional time horizon: Unknown. No timeline is supplied for completing the review, conducting follow-up trials, or applying any findings.

Possible benefits

  • If completed and used by researchers, the evidence map could identify gaps and inform future trials with more consistent definitions and patient-important outcomes. Sources: evidence-2661

Risks and possible harms

  • The language restrictions may omit relevant reports, including from Japan and Korea, and the fast-changing literature may make the review a time-limited snapshot; this could leave gaps in the evidence map. Affected groups: Older endoscopy patients and researchers or clinicians relying on the map, particularly where relevant evidence is reported in excluded languages or published later. Sources: evidence-2660

Distribution and adoption

Who might be excluded

  • The planned review focuses on adults aged 65 and older having gastrointestinal endoscopy; adults under 65 and patients having other procedures are outside this stated population. Sources: evidence-2655
  • Reports published only in languages other than English or Chinese may be excluded, including potentially relevant reports from Japan and Korea. Sources: evidence-2659, evidence-2660

Adoption barriers

  • The planned scoping review will map evidence but will not estimate comparative treatment effects, limiting its direct use for treatment decisions. Sources: evidence-2657, evidence-2658
  • Variation in age definitions, regimens, comparators, and outcome measures may make the mapped studies difficult to compare. Sources: evidence-2656

Assumptions and conditions that could change the assessment

  • The review is completed as planned and its evidence map identifies gaps useful for future research. Sources: evidence-2655, evidence-2661
  • Future trials or guidance use the map; the protocol itself does not establish that this uptake or any resulting clinical benefit will occur. Sources: evidence-2658, evidence-2661
  • Completed review findings would clarify what evidence exists and what gaps remain; the protocol alone provides no treatment conclusions. Sources: evidence-2658
  • Future trials with standardized definitions and patient-important outcomes, followed by use of their results in guidance or care, could strengthen the case for broader societal benefit. Sources: evidence-2661

Citations

  1. evidence-2655 · Remimazolam for sedation in elderly patients undergoing gastrointestinal endoscopy: Protocol for a scoping review · S; h; u; a; n; g; ; T; a; o · 10.1371/journal.pone.0363250 · Captured publisher article text · Open source
  2. evidence-2656 · Remimazolam for sedation in elderly patients undergoing gastrointestinal endoscopy: Protocol for a scoping review · S; h; u; a; n; g; ; T; a; o · 10.1371/journal.pone.0363250 · Captured publisher article text · Open source
  3. evidence-2657 · Remimazolam for sedation in elderly patients undergoing gastrointestinal endoscopy: Protocol for a scoping review · S; h; u; a; n; g; ; T; a; o · 10.1371/journal.pone.0363250 · Captured publisher article text · Open source
  4. evidence-2658 · Remimazolam for sedation in elderly patients undergoing gastrointestinal endoscopy: Protocol for a scoping review · S; h; u; a; n; g; ; T; a; o · 10.1371/journal.pone.0363250 · Captured publisher article text · Open source
  5. evidence-2659 · Remimazolam for sedation in elderly patients undergoing gastrointestinal endoscopy: Protocol for a scoping review · S; h; u; a; n; g; ; T; a; o · 10.1371/journal.pone.0363250 · Captured publisher article text · Open source
  6. evidence-2660 · Remimazolam for sedation in elderly patients undergoing gastrointestinal endoscopy: Protocol for a scoping review · S; h; u; a; n; g; ; T; a; o · 10.1371/journal.pone.0363250 · Captured publisher article text · Open source
  7. evidence-2661 · Remimazolam for sedation in elderly patients undergoing gastrointestinal endoscopy: Protocol for a scoping review · S; h; u; a; n; g; ; T; a; o · 10.1371/journal.pone.0363250 · Captured publisher article text · Open source